Literature DB >> 24327631

Secondary prophylaxis for rheumatic fever: simple concepts, difficult delivery.

Nigel Wilson1.   

Abstract

Registers of those with rheumatic heart disease or a history of acute rheumatic fever (RF) are key to prevent RF recurrences and improve disease control. Randomized controlled trials show intramuscular long-acting benzathine penicillin G is more effective than oral penicillin to prevent recurrences. Although some guidelines recommend three-weekly benzathine penicillin, four weekly is effective if compliance rates are high. Four-weekly penicillin delivery is also preferable to three-weekly regimens for health resource and logistical reasons and for patient acceptability and compliance.

Entities:  

Keywords:  rheumatic fever; secondary prophylaxis

Mesh:

Substances:

Year:  2013        PMID: 24327631     DOI: 10.1177/2150135113497240

Source DB:  PubMed          Journal:  World J Pediatr Congenit Heart Surg        ISSN: 2150-1351


  4 in total

1.  Preliminary consultation on preferred product characteristics of benzathine penicillin G for secondary prophylaxis of rheumatic fever.

Authors:  Rosemary Wyber; Ben J Boyd; Samantha Colquhoun; Bart J Currie; Mark Engel; Joseph Kado; Ganesan Karthikeyan; Mark Sullivan; Anita Saxena; Meru Sheel; Andrew Steer; Joseph Mucumbitsi; Liesl Zühlke; Jonathan Carapetis
Journal:  Drug Deliv Transl Res       Date:  2016-10       Impact factor: 4.617

2.  Failure of oral penicillin as secondary prophylaxis for rheumatic heart disease: a lesson from a low-prevalence rheumatic fever region.

Authors:  S M McGlacken-Byrne; H M Parry; P F Currie; N J Wilson
Journal:  BMJ Case Rep       Date:  2015-11-03

Review 3.  Rheumatic heart disease screening: Current concepts and challenges.

Authors:  Scott Dougherty; Maziar Khorsandi; Philip Herbst
Journal:  Ann Pediatr Cardiol       Date:  2017 Jan-Apr

4.  Enablers and barriers to secondary prophylaxis for rheumatic fever among Māori aged 14-21 in New Zealand: a framework method study.

Authors:  Hilary Barker; John G Oetzel; Nina Scott; Michelle Morley; Polly E Atatoa Carr; Keri Bolton Oetzel
Journal:  Int J Equity Health       Date:  2017-11-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.